Conference Reports for NATAP

Back

IDSA ID Week 2026 October 21-24 Washington, DC     HIV   Impact of Extension for Community Health Outcomes Model for HIV Training in Midwestern Non-Metropolitan Areas - (10/28/26)   Modelling the Future Epidemiological and Economic Burden of HIV in the United States: Substantial New Diagnoses and Additional Costs Projected Under Current Care Patterns - (10/28/26)   Differences in Demographics and HIV Risk Exposures Among People Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Versus Other Post-Exposure Prophylaxis Regimens in the United States, 2016-2025 - (10/28/26)   Routine HIV Screening to Prevention Services: Diversifying Linkage to HIV Prevention Services Across 97 Emergency Departments, Community Health Centers, and High-Impact Settings - (10/28/26)   Potential Drug-Drug Interactions in People Living With HIV on Antiretroviral Therapy Stratified by Age and Sex - (10/22/26)   Switching to Islatravir + Ulonivirine Once Weekly Maintained HIV-1 Viral Suppression at Week 24 in the Presence of Baseline Nonnucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations and M184I/V in Proviral DNA - (10/22/26)   Exposure-Response Analysis of Islatravir 0.25 mg With Doravirine 100 mg Once Daily in Treatment-Naive and Virologically Suppressed People Living With HIV-1 at Week 48 - (10/22/26)   FIVE YEARS OF U.S. REAL-WORLD EVIDENCE REINFORCE THE DURABLE EFFECTIVENESS AND LONG-TERM PERSISTENCE OF ViiVHEALTHCARE'S CABENUVA - (10/22/26)   Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026 - (10/22/26)   PrEP   HIV Testing and Evidence of HIV Among Real-World Long-Acting Pre-Exposure Prophylaxis Users in a United States Claims Database: Updated Results From the PrEPFACTS Study - (10/29/26)   Association of substance use with pre-exposure prophylaxis outcomes among men who have sex with men in the United States: results from the American Men's Internet Survey (AMIS) 2024-25 - (10/28/26)   Changes in Pre-Exposure Prophylaxis Cost Sharing and HIV-1 Diagnoses Following United States Preventive Services Task Force and Affordable Care Act Coverage Milestones: An Interrupted Time Series Analysis - (10/28/26)   Real-World Persistence and Adherence to On-time Injections of Long-acting Cabotegravir for HIV Pre-Exposure Prophylaxis - (10/26/26)   Early Expectations of Cabotegravir Every 4 Month Injections for HIV Pre-exposure Prophylaxis Among Individuals Using Cabotegravir Every 2 Month Injectable - (10/26/26)   Evaluating the National- and State-level Economic and Public Health Effect of Moderate Uptake of a Twice-Yearly Injectable PrEP Coupled With Minimal Overall PrEP Expansion in the General US Population and MSM - (10/26/26)   Racial and Ethnic Differences in Long-Acting Cabotegravir for HIV-1 Pre-Exposure Prophylaxis Experience in a US Real-World Cross-Sectional Study: Results From the CAPTIVATE Study - (10/26/26)   Pre-Exposure Prophylaxis Uptake and Care in Locations of High HIV Incidence for Black Cisgender Women in the US, 2024 - (10/26/26)   Real-World Persistence of Long-Acting Cabotegravir for HIV Pre-Exposure Prophylaxis in the United States: Results From the PrEPFACTS Study Using Healthcare Administrative Claims Data - (10/26/26)   Implementation and Uptake of Lenacapavir Long-acting Injectable PrEP at Duke University Hospital - (10/26/26)   User Experience Concepts Assessed Among People in the United States Using Long-Acting Injectable Cabotegravir for PrEP in Real-World Care: Results From the CAPTIVATE Study - (10/26/26)   Long-acting Injectable PrEP: Interest vs. Access in an Ending the HIV Epidemic Priority State - (10/26/26)   Early Real-World Adoption Patterns of Long-Acting Lenacapavir for HIV PrEP in the United States (June 2025-March 2026) - (10/26/26)   High Suppression and Rare Virologic Failure with Long-Acting Cabotegravir + Rilpivirine: Real World Evidence Over Five Years from the OPERA Cohort - (10/26/26)   High Incidence of Sexually Transmitted Infections and Sexual Behaviors Associated with HIV Acquisition Among Cisgender Men and Gender-Diverse Individuals in PURPOSE 2 - (10/26/26)   Lenacapavir for HIV PrEP: Early Real-World Implementation Insights on Uptake, Patient Pathways, and Injectable Transition Outcomes at a Multi-Site U.S. Clinic Network - (10/26/26)   Low Incidence of Hepatitis B (HBV) Infection Among People Receiving Lenacapavir (LEN) or Tenofovir-Based HIV Pre-exposure Prophylaxis (PrEP) in PURPOSE 1 and PURPOSE 2 - (10/26/26)   Phase 1 Study to Evaluate the Absorption, Metabolism, and Excretion of Alimatravir (MK-8527), a Nucleoside Reverse Transcriptase Translocation Inhibitor, in Adults Without HIV - (10/26/26)   Low Rate of HIV Acquisition on Cabotegravir Pre-Exposure Prophylaxis in OPERA: Possible Long-Acting Early Viral Inhibition Observed - (10/24/26)   Exploring Preferences and Adherence & Persistence among Individuals Initiating PrEP in Portugal: the POSITIVE CARE Study - (10/22/26)   Barriers to PrEP, HIV knowledge and perceived stigma among MSM and Heterosexual People Living with HIV in Portugal: the POSITIVE CARE Study - (10/20/26)   Baseline Characteristics and Substance Use Among People Who Inject Drugs With Evidence of Active Use in HPTN 103/PURPOSE 4: A Phase 2 Study of Twice-Yearly Subcutaneous Lenacapavir for Pre-Exposure Prophylaxi - (10/20/26)   Comorbidities/ Aging   Real-World Effectiveness of High vs Standard Dose Influenza Vaccine in People with HIV: A Retrospective Cohort Study Using the Epic Cosmos Database - (10/27/26)   Cardiovascular Disease as an Emerging Leading Cause of Death in P'eople With HIV: A 26-Year US National Analysis - (10/27/26)   Anal Cytology as a Predictor of Anoscopy Outcomes in People Living with HIV - (10/27/26)   Anal Cancer Screening Program: A Real World, 2-Year Experience at the Atlanta Veterans Affairs Medical Center - (10/27/26)   Lifetime Survivors: Clinical and Demographic Characteristics of Adults with Perinatally Acquired HIV at an Urban Academic Medical Center - (10/27/26)   Estimating the Association of Cannabis Use with Physical and Mental Health in Adults with HIV Disease - (10/24/26)   Recombinant Zoster Vaccination Lowers and Herpes Zoster Infection Raises Incident Heart Failure Risk in People Living with HIV: A Real-World Matched Cohort Study - (10/26/26)   Systematic Review of Factors Associated with Sudden Cardiac Arrest in Persons Living with Human ImmunodeFiciency Virus - (10/26/26)   Ten-Year Cost Projections for Medicare Beneficiaries 65 Years or Older With HIV - (10/23/26)   Projected Aging Among People With HIV in the US - (10/23/26)   Pharmacokinetic and Clinical Data Supporting the LEN Reloading Strategy for BIC/LEN Single-Tablet Regimen Dosing in the ARTISTRY Studies - (10/22/26)   Community HERO Treatment Survey: Characterizing Treatment Journey for Older People with HIV - (10/22/26)   Safety Analysis of BIC/LEN Single-Tablet Regimen in People With HIV Who Have Comorbidities of Dyslipidemia, Hypertension, and Diabetes Mellitus From Phase 3 of ARTISTRY-1 - (10/22/26)   Metabolic and Safety Outcomes With BIC/LEN Single-Tablet Regimen in People With HIV and Comorbidities in ARTISTRY-2 - (10/22/26)   Efficacy and Safety Outcomes With BIC/LEN Single-Tablet Regimen in People With HIV and Renal Impairment in Phase 3 of ARTISTRY-1 - (10/22/26)   Changes in Fasting Lipids and Insulin Resistance After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 96 Results From Two Phase 3 Studies in Adults Living With HIV-1 - (10/22/26)   Trends and Disparities in Statin Use Following Updated Guidelines Among People with HIV Based on 10-year Cardiovascular Risk Levels - (10/20/26)   Gait Speed Assessment During Routine HIV Care to Identify Frailty Risk - (10/20/26)   Statin Prescribing Patterns for Patients with HIV in a Post-REPRIEVE Era: A Retrospective Analysis - (10/20/26)   CKD Screening and Interventions in Patients Living with HIV and Diabetes - (10/20/26)   Implementation of 2024 Statin Guidelines in an Urban HIV Clinic: Changes in Prescribing Practices - (10/20/26)   Factors Associated with Cognitive Performance among People with HIV Aged 60 Years and Older: A Cross-sectional Study Using Normative K-MoCA z-scores - (10/20/26)   ART   Real-World Outcomes With Long-Acting Cabotegravir Plus Rilpivirine in People With High Body Mass Index: A Systematic Literature Review - (10/28/26)   Real-World Virologic Effectiveness Outcomes With Long-Acting Cabotegravir Plus Rilpivirine in People Who Are Treatment-Experienced With Viremia: A Systematic Literature Review and Meta-Analysis - (10/28/26)   Incidence of Resistance-Associated Mutations Among People With HIV Receiving B/F/TAF Versus DTG-Based Regimens - (10/28/26)   High Suppression and Rare Virologic Failure with Long-Acting Cabotegravir + Rilpivirine: Real World Evidence Over Five Years from the OPERA Cohort - (10/26/26)   Single-Dose Escalation Study of TMB-365 in People Living with HIV: Safety, Pharmacokinetics, and Antiviral Activity - (10/26/26)   Long-Acting Cabotegravir+Rilpivirine in People with HIV with Obesity (BMI>/= 30 kg/m2): High Durability with Distinct Discontinuation Patterns - (10/26/26)   Efficacy and Safety by Demographic Subgroup After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 96 Results From Two Randomized, Active-Controlled Phase 3 Studies in Adults Living With HIV-1 - (10/26/26)   TMB-365 and TMB-380: A potentially resistance repellant stand-alone maintenance bNAb regimen in suppressed people living with HIV-1 on combination antiretroviral therapy - (10/26/26)   Long-Acting Cabotegravir plus Rilpivirine in People With HIV Aged ≥60 Years: Real-World Evidence From the RELATIVITY Cohort in the Context of Multimorbidity - (10/26/26)   Patient-Reported Outcomes From Virologically Suppressed Adults Living With HIV-1 Switching to Once-Weekly Oral Islatravir in Combination With Ulonivirine: Phase 2b Week 24 Results - (10/26/26)   Immune Recovery Continues to Improve Over 5 Years With Fostemsavir Despite Emergent gp120 Substitutions - (10/24/26)   Real-World Experience with Injectable -Based Lenacapavir Regimens in Patients with HIV-1: A Descriptive Study - (10/24/26)   Real-World Virologic Effectiveness Outcomes With Long-Acting Cabotegravir Plus Rilpivirine in People Who Are Treatment-Experienced With Viremia: A Systematic Literature Review and Meta-Analysis - (10/24/26)   Efficacy and Safety of Once-Weekly Oral Islatravir/Lenacapavir (ISL/LEN) Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) or Standard of Care (SOC) in People With HIV-1 (PWH) and Virologic Suppression: Week 48 Integrated Analysis From the Phase 3 ISLEND-1 and ISLEND-2 Trials - (10/24/26)   TaiMed Biologics Reports IDWeek 2026 Data Highlighting TMB-365 and Its Potential Across Long-Acting HIV Combinations - (10/23/26)   Weight and Metabolic Outcomes in People Living with HIV Following Switch to Long-Acting Cabotegravir/Rilpivirine: A Retrospective Cohort Study - (10/23/26)   Long-term Outcomes of Cabotegravir-Rilpivirine Long-Acting Injectable Initiated in People with HIV with Recent Viremia: A National VHA Cohort Study - (10/23/26)   Historical Genotype Availability and Outcomes After Switching to Long- Acting Cabotegravir Plus Rilpivirine: The RELATIVITY Cohort - (10/23/26)   Long-Term Durability and Virological Effectiveness of Long-Acting Cabotegravir plus Rilpivirine in Routine HIV Care: Updated Real-World Data from the Spanish RELATIVITY Cohort - (10/23/26)   Longitudinal Adherence to Long-Acting Cabotegravir plus Rilpivirine in Routine Clinical Practice: Updated Temporal Trends from the RELATIVITY Cohort in Spain - (10/23/26)   Dolutegravir + Lamivudine in People With HIV-1 Who Are Naive to Antiretroviral Therapy With Baseline Viral Load ≥500,000 c/mL: Systematic Literature Review and Meta-Analysis of Real-World Evidence - (10/23/26)   Virologic Outcomes by ART Initiation Timing: Sub-Analysis of the REVIVE Study (DTG/3TC & BIC/F/TAF) - (10/23/26)   Mental Health among Patients Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in an Urban Midwestern HIV Clinic: A Retrospective Cohort Study - (10/23/26)   Virologic Outcomes of Individuals Prescribed Dolutegravir/Lamivudine After an Oral Antiretroviral Therapy Treatment Interruption: Findings from the OPERA Cohort - (10/23/26)   High rates of HIV virologic suppression after initiation of long-acting injectable antiviral agents among patients with virologic failure in an urban health system - (10/23/26)   Advancing Equity in the Delivery of Long-acting Injectable Antiretroviral Therapy: Preliminary Results of the IM-CAPABLE Study - (10/23/26)   Virologic Outcomes Following Transition to Long-Acting Injectable Cabotegravir/Rilpivirine: Comparison of Prior Two-Drug vs Three-Drug Oral Regimens - (10/23/26)   Preference for receiving long-acting injectable (LAI) ART at home: Differences among reproductive-aged women in the U.S. South - (10/23/26)   Persistence and Virologic Outcomes at 12 Months After Switch to Long-Acting Cabotegravir-Rilpivirine in Veterans With HIV: A Nationwide Matched Cohort Study - (10/23/26)   Predictors of Successful Switch to Long-Acting Cabotegravir/Rilpivirine in a National Veterans Health Administration Cohort - (10/23/26)   The Evolution of Integrase Strand Transfer Inhibitors: VH-184, a Third-Generation Inhibitor With an Enhanced Resistance Profile - (10/23/26)   Virological Effectiveness of B/F/TAF Despite Suboptimal Adherence Measured by Electronic Monitoring in a Socially Vulnerable Real-World Cohort - (10/23/26)   Week 48 Efficacy and Safety of Doravirine/Islatravir (100 mg/0.25 mg) vs Bictegravir/Emtricitabine/Tenofovir Alafenamide in Previously Untreated Adults Living With HIV-1 With Renal Impairment - (10/22/26)   Hepatitis   Advancing Chronic Hepatitis Delta Therapy: Efficacy of Tobevibart (VIR-3434) + Elebsiran (VIR-2218) in Chronic Hepatitis Delta Infection - (10/27/26)   Others   Safety and Tolerability of GS-1179, a Novel, Oral, Long-Acting HSV Helicase-Primase Inhibitor for Recurrent Genital Herpes: Results From a Phase 1b Study - (10/27/26)   Efficacy and Virologic Analyses of GS-1179, a Novel, Oral, Long-Acting HSV Helicase-Primase Inhibitor for Recurrent Genital Herpes: Results From a Phase 1b Study - (10/27/26)